Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 220

Sort by

Sort Order Select

Journal Articles

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stephanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoit Tessoulin, Charles Herbaux, Steven Le Gouill, Clementine Sarkozy

Blood (2024) 144 (Supplement 1): 239.

https://doi.org/10.1182/blood-2024-198920

Published: 2024

Journal Articles

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Benoit Tessoulin, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Cedric Rossi, Caroline Milin, Ludovic Fouillet, Charles Herbaux, Emmanuelle Tchernonog, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2024-206778

Published: 2024

Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart

Blood (2024) 144 (Supplement 1): 745.

https://doi.org/10.1182/blood-2024-194357

Published: 2024

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 3129.

https://doi.org/10.1182/blood-2024-203186

Published: 2024

Journal Articles

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

Mary B. Callanan, Caroline Milin, Marie-Helene Delfau-Larue, Clément Bailly, Clémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, Emmanuel Gyan, Krimo Bouabdallah, Remy Gressin, Gandhi Damaj, Olivier Casasnovas, Vincent Ribrag, Samuel Griolet, Barbara Burroni, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2024-208081

Published: 2024

Journal Articles

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood (2024) 144 (3): 262–271.

https://doi.org/10.1182/blood.2024023944

Published: 2024

Includes: Supplemental data

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Jurik A Mutter, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Stefan K. Alig, Mark P. Hamilton, Brian J. Sworder, Benoit Tessoulin, Jan Boegeholz, Timothy Flerlage, Jamie E. Flerlage, Michael S. Binkley, Takeshi Sugio, Cédric Rossi, Mari Olsen, Chih Long Liu, Steven Le Gouill, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 245.

https://doi.org/10.1182/blood-2023-186853

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Journal Articles

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Blood (2023) 142 (18): 1543–1555.

https://doi.org/10.1182/blood.2023020211

Published: 2023

Includes: Supplemental data

Journal Articles

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Blood (2023) 142 (Supplement 1): 979.

https://doi.org/10.1182/blood-2023-188788

Published: 2023

Journal Articles

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Loic Ysebaert, Roch Houot, Olivier Casasnovas, Choquet Sylvain, Fabrice Jardin, Michael Loschi, Gabriel Brisou, Catherine Thieblemont, Jacques-Olivier Bay, Cristina Castilla-Llorente, Tom Fradon, Steven Le Gouill, Franck Morschhauser, Guillaume Cartron, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 296.

https://doi.org/10.1182/blood-2023-184653

Published: 2023

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2023-188655

Published: 2023

Journal Articles

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clementine Sarkozy, Mary Callanan, Catherine Thieblemont, Lucie Oberic, Barbara Burroni, Krimo Bouabdallah, Gandhi Laurent Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Houot, Franck Morschhauser, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 980.

https://doi.org/10.1182/blood-2023-174416

Published: 2023

Journal Articles

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Eric Durot, Damien Roos-Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Hedi Bensader, Morgane Cheminant, Caroline Jacquet, Stephanie Guidez, François-Xavier Gros, Emmanuel Bachy, Pascale Cony-Makhoul, Steven P Treon, Alain Jacques Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot

Blood (2023) 142 (Supplement 1): 616.

https://doi.org/10.1182/blood-2023-173988

Published: 2023

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2023-173265

Published: 2023

NARROW

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only